12 patents
Utility
Compositions and methods for treating and preventing staphylococcus aureus infections
11 Jan 24
Methods and compositions for treating a Staphylococcus aureus bloodstream infection in a human subject involve administering to the subject an antibody which specifically binds Staphylococcus aureus protein A (SpA) with a K D of less than 1×10−10 M via its Fab region paratope and is able to mediate opsonization of SpA-expressing Staphylococcus aureus bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.
John Simard
Filed: 11 Sep 23
Utility
True human antibody specific for interleukin 1 alpha
12 Oct 23
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
John Simard, Sushma Shivaswamy, Galina Kuzmicheva
Filed: 3 Apr 23
Utility
qhyzt1it3mdardiwibcs
14 Sep 23
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
John Simard, Sushma Shivaswamy, Galina Kuzmicheva
Filed: 3 Apr 23
Utility
zzzlvqjmt61ndmrt3pscx4xegw0t56g44ky4
14 Sep 23
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
John Simard, Sushma Shivaswamy, Galina Kuzmicheva
Filed: 3 Apr 23
Utility
6p9eqixboy0hs4cmov4vfkjsl0uwsfyzomkagc73yg5ghgmw8fwgaw3
14 Sep 23
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
John Simard, Sushma Shivaswamy, Galina Kuzmicheva
Filed: 3 Apr 23
Utility
acaky2e9xc3n8bgf5nhfmedsm9s2qce5nlb6gfpvtcsxhrw
11 Aug 22
Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A.
John Simard
Filed: 15 Apr 22
Utility
4os03k8yb5z11m6fw 0g3kr3npwt3dftsrw41f4v
10 Feb 22
The sequelae of cerebral ischemia-reperfusion injury are reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.
Giovanni Guido Camici, Luca Liberale, Peter Libby, John Simard
Filed: 23 Oct 21
Utility
ss5kc0176qyq9h9rcralmc
21 Jan 21
Methods and compositions for treating a Staphylococcus aureus bloodstream infection in a human subject involve administering to the subject an antibody which specifically binds Staphylococcus aureus protein A (SpA) with a KD of less than 1×10−10 M via its Fab region paratope and is able to mediate opsinization of SpA-expressing Staphylococcus aureus bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.
John Simard
Filed: 28 Jun 18
Utility
zh9c9o5t7dd41zkytxdfm9xg0bbz9v1jjkt9ermff8wmtn
29 Apr 20
Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A.
John Simard
Filed: 7 Jan 20
Utility
6t2h0f33rc56jbtvhbtznukwhru7cz6xzfr8m40k8d 23srsr
4 Mar 20
Antigen-specific immunoglobulin V-regions are identified from a library of nucleic acids amplified using polymerase chain reaction using leader sequence-specific forward primers.
John Simard
Filed: 18 Nov 19
Utility
jqu69fjeic806wy7vqfm73lnbbw0yj1kq1v1rcm8vmjtqmr8vs
25 Dec 19
Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.
Evangelos J. Giamarellos-Bourboulis, Stanley A. Kim
Filed: 13 Aug 19
Utility
bsrykykx9xfo gur9xyc67f6blv2xcvkqls1m1m
20 Nov 19
Administration of a monoclonal Ab (mAb) that specifically targets IL-1α is useful to treating articular and extra-articular symptoms of arthritis.
John Simard
Filed: 1 Aug 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first